Drugs / Somatuline ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05364944 Background | May 2022 → Oct 2024 | acromegaly, digestive system neuroendocrine neoplasm | Debiopharm International SA | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Somatuline ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05364944 ↗ |
| Route | Subcutaneous | “Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration” NCT05364944 ↗ |